Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Mol Cancer Res. 2018 Jan 12;16(4):599–609. doi: 10.1158/1541-7786.MCR-17-0492

Figure 1.

Figure 1

Drugs targeting the Her2-Akt-mTOR pathway induce Par-4 upregulation in Her2-amplified breast cancer cells. A and B, Treatment of the Her2-amplified cell lines BT-474 and SKBR3 with Lapatinib for 2 days induces Par-4 protein (A) and mRNA (B) upregulation. C, Time-course of Par-4 mRNA upregulation following Lapatinib treatment in BT-474 cells. D and E, Western blot (D) and qPCR (E) analysis showing Par-4 upregulation in BT-474 cells treated with Lapatinib, the Akt inhibitor MK-2206, or the mTOR inhibitor Torin1 for 2 days. Significance was determined by Student’s t-test and data are presented as mean plus standard deviation (SD). **, p<0.01; ***, p<0.001.

HHS Vulnerability Disclosure